Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544147 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL30544125 | 0.78 | CA12 (0.35) | TRPV1 | |
| SCHEMBL25339908 | 0.78 | CA12 (0.35) | TRPV1 | |
| SCHEMBL25955304 | 0.77 | CYP1A2 (0.33) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL30544079 | 0.74 | GPR142 (0.36) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL25339990 | 0.74 | GPR142 (0.36) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL25973977 | 0.71 | TRPV1 (0.39) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL25429595 | 0.70 | TRPV1 (0.37) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL30544122 | 0.70 | TRPV1 (0.37) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL25954052 | 0.70 | TRPV1 (0.37) | CYP1A2CYP3A4GAACYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |